Page 11 - Human Use News Today

First non-immunosuppressive therapy for the treatment of IgA nephropathy approved in Europe Conditional marketing authorization is based on statistically significant and clinically meaningful...

Today (April 24), Astellas Pharma Inc. revealed that XTANDITM (enzalutamide) has received a label extension from the European Commission, marking it as the inaugural and only novel hormone therapy endorsed for high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC) treatment in the European Union (EU).

The European Commission has approved enzalutamide as monotherapy and in combination with ADT in BCR nonmetastatic hormone-sensitive prostate cancer.

AstraZeneca announces that Voydeya has been approved in the European Union as an adjunct to ravulizumab or eculizumab for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria ...

Tislelizumab has been approved in Europe across 3 indications in the first and second line for select patients with non–small cell lung cancer.

The factor D inhibitor danicopan has been approved for use in Europe for patients with paroxysmal nocturnal hemoglobinuria with residual hemolytic anemia on standard therapy.

UCB receives European Commission approval for BIMZELX[®]▼ as the first IL-17A and IL-17F biologic for moderate to severe hidradenitis suppurativa ...

Explore the latest trends and innovations in drug development and the role organizations play in overcoming challenges

MALVERN, Pa., April 10, 2024 -- Ocugen, Inc. , a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that the...

The EMA’s Committee for Medicinal Products for Human Use recommendation for marketing authorisation means we are one step closer to treating adult patients with complicated intra-abdominal and urinary tract infections and hospital-acquired pneumonias caused by Gram-negative bacteria.